Document is current
Any future updates will be listed below
-
Authors
Martin, Helene Meyer
Näslund-Koch, Charlotte
Løvendorf, Marianne Bengtson
Bojesen, Stig Egil
Kobylecki, Camilla J.
Vedel-Krogh, Signe
Skov, Lone
-
Funding
Funding for this research was provided by:
LEO Fondet (LF-ST-21-500002)
- License Information
-
More Information
Article History
Received: 26 June 2025
Accepted: 25 November 2025
First Online: 18 December 2025
Declarations
:
: HMM, SVK, CJB, SEB and MBL report no conflicts of interest. CNK has served as an investigator for Galderma, Abbvie, LEO Pharma, Novartis, and CSL Behring. She has received honoraria as consultant and/or speaker and travel grant from LEO Pharma and UCB. LS has received research funding from Novartis, Bristol-Myers Squibb, AbbVie, Janssen, the Danish National Psoriasis Foundation, the LEO Foundation and the Kgl Hofbundtmager Aage Bang Foundation and honoraria as consultant and/or speaker for AbbVie, Eli Lilly, Novartis, Pfizer, and LEO Pharma, Janssen, UCB, Almirall, Bristol-Myers Squibb, and Sanofi. She has served as an investigator for AbbVie, Pfizer, Sanofi, Janssen, Boehringer Ingelheim, AstraZeneca, Eli Lilly, Novartis, Regeneron, Galderma and LEO Pharma.
